Analysis of additional granulocyte and monocyte adsorption therapy for incomplete remission induction in ulcerative colitis

Analysis of additional granulocyte and monocyte adsorption therapy for incomplete remission induction in ulcerative colitis - Additional treatment with GMA in UC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049168

Enrollment

194

Registered

2022-10-09

Start date

2021-10-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Ulcerative colitis patients who underwent outpatient or inpatient granulocyte/monocyte adsorption at our hospital between August 1, 2012 and May 31, 2021.

Exclusion criteria

Exclusion criteria: Patients who oral administration adherence is less than 80%. Patients who did not complete granulocyte/monocyte adsorption because of vascular securing difficulty. Patients who treated with granulocyte/monocyte adsorption monotherapy.

Design outcomes

Primary

Measure	Time frame
The success rate of remission induction with granulocyte/monocyte adsorption combination.	—

Secondary

Measure	Time frame
Treatment success rates by timing of granulocyte/monocyte adsorption addition, comparison of days to induction of remission, incidence of incident events, and steroid-free remission rates at 52 weeks.	—

Countries

Japan

Contacts

Public ContactMimari Kanazawa

Dokkyo Medical University School of Medicine Department of Gastroenterology

mimari77@dokkyomed.ac.jp+81-282-87-2147

Outcome results